Dutasteride and finasteride can cause watery ejaculate, which may persist for some users. Zinc supplements or switching to topical treatments are suggested to alleviate this side effect.
Scalp tension from the occipitalis muscle is theorized to contribute to hair loss, but most believe DHT and genetics are the main causes. Treatments like finasteride and minoxidil are considered more effective than addressing scalp tension.
A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.
Bee venom at 0.001% concentration was more effective than 2% minoxidil in promoting hair growth in mice, possibly due to increased growth factors and reduced inflammation. Caution is advised due to potential allergic reactions and the reliance on animal data.
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
Finasteride users may have an increased risk of depression, anxiety, and suicidal thoughts, though some attribute these issues to hair loss itself. The link between finasteride and mental health effects is debated, with varying user experiences.
PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.
Hair loss greatly affects mental health and social life for young men. Treatments like finasteride, minoxidil, and hair transplants are common, with mixed success and ongoing self-esteem challenges.
PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.
The user reports significant hair regrowth after 200 days using dutasteride and minoxidil, attributing changes to hair dye. Others doubt the authenticity and discuss treatment effectiveness and side effects.
Finasteride is generally seen as more successful for hair loss than Dutasteride, with fewer negative experiences reported. Dutasteride is considered more effective but often leads to more complaints, possibly due to higher expectations or improper use.
The user has used oral Dutasteride and Minoxidil for two years without regrowth, despite trying Finasteride and supplements. They consider increasing Minoxidil, adding microneedling, and switching medications, while others suggest RU58841, a hair transplant, or checking for other hair loss causes.
Beard gains from minoxidil are usually permanent due to facial hair follicles' lower sensitivity to DHT. Scalp hair requires ongoing DHT suppression with treatments like finasteride, dutasteride, and RU58841 to maintain gains after stopping minoxidil.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
Hair loss affects self-esteem and mental health, with treatments like finasteride and minoxidil commonly used. People feel misunderstood by those without hair loss and seek more empathy and better treatment options.
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
Concerns about the long-term effects of dutasteride and finasteride on fertility, with discussions on cycling these medications to mitigate risks. The conversation highlights skepticism about study methodologies and the importance of weighing treatment risks against potential fertility issues.
Dutasteride caused persistent hair shedding and no improvement for 18 months, leading to a switch back to finasteride. The user also uses oral minoxidil and plans to focus on better scalp health.
An 18-year-old is using finasteride for hair loss prevention despite having a healthy hairline. Opinions are mixed, with some advising against its use at his age and others supporting his proactive approach.
PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.
A 19-year-old saw significant hair regrowth using 5% minoxidil over three months, with only initial shedding as a side effect. They plan to continue minoxidil and may add finasteride to maintain results.
Dutasteride is more effective than Finasteride for hair loss, with similar safety profiles. Individual responses vary, and factors like Minoxidil use and age differences may influence results.
The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.
A 17-year-old improved his hairline using minoxidil and derma stamping, planning to start finasteride at 18. He received advice on dosing and potential side effects to maintain results.
Way-316606 is considered a potential hair loss treatment but is avoided due to safety concerns and lack of research. Minoxidil and Finasteride are preferred as established treatments.
Finasteride is debated for causing dry eyes, with some users experiencing relief after stopping it, while others find no connection. Topical treatments like dutasteride and minoxidil are suggested as alternatives, with advice to consult medical professionals.
The user has been using a combination of oral finasteride, oral dutasteride, topical and oral minoxidil, microneedling, and keto shampoo for hair loss, experiencing significant shedding recently. Suggestions include simplifying the regimen by dropping finasteride and topical minoxidil, and possibly adding RU58841, while others advise maintaining the current approach for consistent results.
A 24-year-old male using dutasteride for hair loss is worried about its effects on fertility and future children's health. Users advise consulting a doctor, possibly switching to finasteride, or stopping dutasteride before conception due to its impact on sperm count.
Dutasteride is safer than finasteride for long-term use, with fewer sexual side effects. Users experience better hair regrowth and fewer side effects with dutasteride.
PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.